|
RABEP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.43000000010873E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.83600000003281E-06 |
| Normal-vs-Stage2 |
4.631600E-02 |
| Normal-vs-Stage3 |
1.08509999985351E-07 |
| Normal-vs-Stage4 |
5.48669998323703E-09 |
| Stage1-vs-Stage2 |
5.942100E-02 |
| Stage1-vs-Stage3 |
1.757390E-01 |
| Stage1-vs-Stage4 |
4.789900E-02 |
| Stage2-vs-Stage3 |
1.032090E-02 |
| Stage2-vs-Stage4 |
2.484700E-03 |
| Stage3-vs-Stage4 |
3.804200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.18009999994229E-07 |
| Normal-vs-AfricanAmerican |
3.797100E-03 |
| Normal-vs-Asian |
2.0397999999977E-05 |
| Caucasian-vs-AfricanAmerican |
5.167400E-01 |
| Caucasian-vs-Asian |
8.145800E-01 |
| AfricanAmerican-vs-Asian |
4.676200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.86589999509701E-08 |
| Normal-vs-Female |
1.89640000036739E-07 |
| Male-vs-Female |
2.536200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.24799999999359E-05 |
| Normal-vs-Age(41-60Yrs) |
7.24790000239395E-08 |
| Normal-vs-Age(61-80Yrs) |
4.48510000000679E-05 |
| Normal-vs-Age(81-100Yrs) |
1.702060E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.540590E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.495000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.459400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.454000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.210800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.572800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.448400E-02 |
| Classical-VS-Follicular |
9.609400E-01 |
| Classical-VS-Other |
1.283360E-01 |
| Classical-VS-Normal |
2.40419999997243E-06 |
| Tall-VS-Follicular |
5.790100E-02 |
| Tall-VS-Other |
6.037800E-01 |
| Tall-VS-Normal |
3.62310000001642E-07 |
| Follicular-VS-Other |
2.018800E-01 |
| Follicular-VS-Normal |
1.814300E-04 |
| Other-VS-Normal |
5.249700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.72870000039838E-07 |
| Normal-vs-N1 |
1.88090000019514E-07 |
| N0-vs-N1 |
7.515700E-02 |
|
|
